Data-Sharing, Failure Incentives Could Accelerate R&D, Investors Say
This article was originally published in The Pink Sheet Daily
Changes to the traditional drug development model, like incentives that encourage researchers to kill unsuccessful projects earlier in development and open access to data, will improve the drug development cycle – and investor sentiment in biotech/pharma, panelists say during FasterCures’ Partnering For Cures conference.
You may also be interested in...
The company will cut 340 positions, primarily affecting Zulresso commercial operations, to save $170m, after announcing it will need to run new trials to support the regulatory plan for zuranolone.
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
A Phase III trial testing dapagliflozin in chronic kidney disease patients with and without diabetes was stopped early following a recommendation from an independent data monitoring committee.